Viatris: Watch Out For Potential Complex Injectable Launches In 2023
As Firm Welcomes Generics ‘Momentum We Have Never Seen Before’
Viatris has again the lauded the potential of its complex injectables and steriles pipeline, as it looks to build a business generating revenues of up to $1bn per year within the next five years.
